Navigation Links
OraVerse® Named as One of Dentistry Today's 'Top 100 Products' for Second Year

SAN DIEGO, Aug. 2 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a specialty pharmaceutical company focused in dental, today announced that OraVerse®, the company's premier pharmaceutical product, has again been selected by leading dental industry magazine Dentistry Today as one of its 'Top 100 Products' for 2010.  The full results of the 24th annual competition were published in the July issue.  

OraVerse is the first and only local anesthesia reversal agent that accelerates the return to normal sensation and function for patients who want to avoid the unwanted and unnecessary lingering soft tissue anesthesia following routine dental procedures.  The first-in-class product is currently available to dentists directly from Novalar.  

"Since launch, OraVerse has performed remarkably well in numerous independent product assessments, evaluations and surveys with both dentists and patients," said Donna Janson, President & CEO of Novalar.  "We are extremely proud that the readers of Dentistry Today have selected OraVerse for this distinction two years in a row.  It is truly a breakthrough dental product."  

The 'Top 100 Products' list has honored new and innovative dental products for 24 years.  Products included on the list are selected on the basis of reader response.  Clinical data for OraVerse has also been published in a number of leading peer reviewed scientific journals including the nation's leading dental publication, the Journal of the American Dental Association.

About OraVerse®

OraVerse is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used.  OraVerse is indicated for reversal of the soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs).  For more information visit  

Important Safety Information

In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.

About Novalar®

Novalar is a specialty pharmaceutical company that partners directly with dental professionals to enrich the patient experience. The company is uniquely positioned to develop targeted oral pharmaceutical products and translate the full value of these novel solutions to clinical practice. For more information, please visit

SOURCE Novalar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
2. Aspirin Named 8th World Wonder by Majority of Americans
3. American Board of Internal Medicine President Named to Alzheimers Study Group
4. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
5. Pharmaxis Establishes Named Patient Program for Bronchitol
6. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
7. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
8. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
9. Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
Post Your Comments:
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):